These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31258466)

  • 21. Small-molecule PET Tracers for Imaging Proteinopathies.
    Mathis CA; Lopresti BJ; Ikonomovic MD; Klunk WE
    Semin Nucl Med; 2017 Sep; 47(5):553-575. PubMed ID: 28826526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals.
    Schultz AP; Chhatwal JP; Hedden T; Mormino EC; Hanseeuw BJ; Sepulcre J; Huijbers W; LaPoint M; Buckley RF; Johnson KA; Sperling RA
    J Neurosci; 2017 Apr; 37(16):4323-4331. PubMed ID: 28314821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity.
    Val-Laillet D; Aarts E; Weber B; Ferrari M; Quaresima V; Stoeckel LE; Alonso-Alonso M; Audette M; Malbert CH; Stice E
    Neuroimage Clin; 2015; 8():1-31. PubMed ID: 26110109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular neuroimaging in degenerative dementias.
    Jiménez Bonilla JF; Carril Carril JM
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):301-9. PubMed ID: 23933381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease.
    Pandya S; Kuceyeski A; Raj A;
    J Alzheimers Dis; 2017; 55(4):1639-1657. PubMed ID: 27911289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Functional Connectivity in the Brain Using Positron Emission Tomography: A Mini-Review.
    Watabe T; Hatazawa J
    Front Neurosci; 2019; 13():775. PubMed ID: 31402852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
    Gulyás B; Halldin C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tau-imaging in neurodegeneration.
    Bischof GN; Endepols H; van Eimeren T; Drzezga A
    Methods; 2017 Nov; 130():114-123. PubMed ID: 28790016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update.
    Farid K; Charidimou A; Baron JC
    Neuroimage Clin; 2017; 15():247-263. PubMed ID: 28560150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria.
    Caminiti SP; Sala A; Iaccarino L; Beretta L; Pilotto A; Gianolli L; Iannaccone S; Magnani G; Padovani A; Ferini-Strambi L; Perani D
    Alzheimers Res Ther; 2019 Feb; 11(1):20. PubMed ID: 30797240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
    Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.
    Wren MC; Lashley T; Årstad E; Sander K
    Acta Neuropathol Commun; 2018 May; 6(1):34. PubMed ID: 29716656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New protein deposition tracers in the pipeline.
    Jovalekic A; Koglin N; Mueller A; Stephens AW
    EJNMMI Radiopharm Chem; 2017; 1(1):11. PubMed ID: 29564387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography.
    Wang YT; Edison P
    Curr Neurol Neurosci Rep; 2019 Jun; 19(7):45. PubMed ID: 31172290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET.
    Matsuda H; Shigemoto Y; Sato N
    Jpn J Radiol; 2019 Nov; 37(11):735-749. PubMed ID: 31493197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurological update: neuroimaging in dementia.
    Rittman T
    J Neurol; 2020 Nov; 267(11):3429-3435. PubMed ID: 32638104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers.
    Shah M; Catafau AM
    J Nucl Med; 2014 Jun; 55(6):871-4. PubMed ID: 24833492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neural substrates of cognitive reserve in Alzheimer's disease spectrum and normal aging.
    Lee DH; Lee P; Seo SW; Roh JH; Oh M; Oh JS; Oh SJ; Kim JS; Jeong Y
    Neuroimage; 2019 Feb; 186():690-702. PubMed ID: 30503934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal and spectral characteristics of dynamic functional connectivity between resting-state networks reveal information beyond static connectivity.
    Chiang S; Vankov ER; Yeh HJ; Guindani M; Vannucci M; Haneef Z; Stern JM
    PLoS One; 2018; 13(1):e0190220. PubMed ID: 29320526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A perspective on the future role of brain pet imaging in exercise science.
    Boecker H; Drzezga A
    Neuroimage; 2016 May; 131():73-80. PubMed ID: 26477649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.